INTRODUCTION:

The debate surrounding C. sativa—both as an industrial resource and a psychotropic substance—has ignited passionate discussions about its legalization, therapeutic benefits, and societal impacts. From ancient medicinal texts to modern clinical research, C. sativa has played a significant role in shaping human history and continues to influence science, society, and public policy.

This article delves into the botanical features, chemical makeup, historical applications, medical and recreational uses, industrial significance, legal considerations, and cutting-edge research related to C. sativa, drawing on 40-50 scholarly sources.

Botanical Characteristics:

This plant can grow anywhere from one to five meters tall, featuring slender, fibrous stems and palmate leaves with 5 to 7 serrated leaflets.⁵ Its ability to thrive in a range of temperatures–from the temperate climates of Europe to the tropical regions of Asia–has made it a popular choice for cultivation across different continents.¹ The root system of this plant is robust, reaching deep into the soil, which enhances its use in phytoremediation for cleaning up contaminated land.⁶

C. sativa is divided into two subspecies: Sativa (hemp) indica (marijuana), though some argue for a third, C. ruderalis.⁷ Hemp, containing less than 0.3% delta-9-tetrahydrocannabinol (THC), is grown for industrial products like textiles and paper, while marijuana, with higher THC, is used for medicinal and recreational purposes.⁸ Genetic diversity among C. sativa strains, driven by selective breeding, results in varied cannabinoid and terpene profiles, influencing both industrial and pharmacological applications.⁹ For example, modern cultivars like “Charlotte’s Web” are bred for high CBD content, while others maximize THC for psychoactive effects.¹⁰ Cultivation techniques, including hydroponics and controlled lighting, have optimized yield and potency, particularly for indoor marijuana production.¹¹

However, outdoor hemp cultivation remains more sustainable, requiring fewer resources and supporting biodiversity.¹² These botanical and agricultural nuances underscore C. sativa’s versatility and its role in both traditional and modern economies.¹

Chemical Composition:

Cannabinoid effects might be regulated through what's known as the "entourage effect," where different components work together in a synergistic way. For instance, myrcene can enhance the calming effects of THC, while limonene might help reduce anxiety. Additionally, flavonoids like cannflavins possess anti-inflammatory properties, contributing to the plant's overall therapeutic potential.¹⁹

The differences in chemical composition among various strains, their growing conditions, and the methods used in processing make it tough to achieve consistency, particularly in medicinal uses.²² Nowadays, cannabis products are analyzed using cutting-edge scientific methods like gas chromatography, which helps guarantee their potency and safety.²³ Historic and Cultural Significance: Cannabis boasts a rich history spanning over 5,000 years. Archaeological findings from China indicate its use for fibers and seeds as far back as 3000 BCE, with hemp ropes and textiles discovered in ancient burial sites.²⁴ Cannabis sativa contains over 500 compounds, including cannabinoids, terpenes, flavonoids, and alkaloids, making it one of the most chemically complex plants.¹³

The Chinese Shennong Bencaojing (c. 100 CE) documented cannabis’s medicinal properties for pain, inflammation, and “wind” disorders.²⁵ In India, cannabis was integral to Ayurvedic medicine and Hindu rituals, with texts like the Atharvaveda describing it as a sacred herb.²⁶

Ancient Egyptians used cannabis for gynecological conditions, as noted in the Ebers Papyrus (c. 1550 BCE).²⁷ By the 19th century, cannabis tinctures were a staple in Western medicine, prescribed for migraines, seizures, and insomnia.²⁸ Sir William O’Shaughnessy, an Irish physician, introduced cannabis to European medicine after studying its use in India.²⁹ However, the early 20th century saw prohibition, driven by social and political factors. The 1937 U.S. Marihuana Tax Act banned cannabis, fueled by propaganda linking it to crime and moral decay.³⁰ The 1960s counterculture movement revived interest, with cannabis becoming a symbol of rebellion and creativity.³¹

Today, cannabis holds cultural significance in contexts like Rastafarian spirituality, where it is used sacramentally.³² Advocacy for drug policy reform, particularly addressing racial disparities in cannabis-related arrests, has further elevated its cultural relevance.² These historical shifts highlight C. sativa’s enduring impact on human societies.

Medical Applications:

The therapeutic potential of Cannabis sativa is a major focus of modern research. CBD is FDA-approved for treating epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome, through the drug Epidiolex.³³ Clinical trials support CBD’s efficacy for anxiety, psychosis, post-traumatic stress disorder (PTSD), and schizophrenia.^34,35 For example, a 2019 study found CBD reduced anxiety in 79% of participants with minimal side effects.³⁶ THC-based medications, such as dronabinol and nabilone, are approved for chemotherapy-induced nausea and appetite stimulation in AIDS patients.³⁷ Cannabis is also widely used for chronic pain management, with meta-analyses indicating moderate efficacy, particularly for neuropathic pain.³⁸ Observational studies suggest cannabis may reduce opioid use in pain patients, potentially mitigating the opioid crisis.^39,40

A 2014 study linked medical cannabis laws to a 25% reduction in opioid overdose deaths.³⁹ Emerging applications include cannabis for neurodegenerative diseases like Alzheimer’s, where preclinical studies suggest cannabinoids may reduce amyloid plaque formation.⁴¹ Cannabis is also explored for inflammatory bowel disease, multiple sclerosis, and cancer symptom management.⁴² However, risks such as cognitive impairment, psychosis, and dependency with high-THC products necessitate cautious prescribing.⁴³ Delivery methods–inhalation, edibles, topicals, or sublingual tinctures–further complicate dosing and bioavailability, requiring standardized protocols.⁴⁴ Recreational Use and Public Health Recreational cannabis is valued for its euphoric, relaxing, and sensory-enhancing effects, driven by THC’s activation of CB1 receptors.¹⁴

Legalization in countries like Canada (2018) and Uruguay (2013) has increased access, generating billions in tax revenue but raising public health concerns.⁴⁵ Studies report a rise in cannabis use among youth in legalized regions, with potential risks to cognitive development and academic performance.³¹ Cannabis use disorder affects approximately 10% of regular users, characterized by dependence, tolerance, and withdrawal symptoms like irritability and insomnia.⁴⁶ High-potency products, with THC levels exceeding 20%, increase risks of psychosis and anxiety, particularly in genetically predisposed individuals.⁴³ Public health campaigns emphasize responsible use, warning against driving under the influence and adolescent use.⁴⁷ Social equity issues are critical, as marginalized groups face disproportionate incarceration for cannabis offenses despite legalization trends.² For example, Black Americans are nearly four times more likely to be arrested for cannabis possession than whites.² Decriminalization and expungement programs aim to address these disparities, but challenges remain in ensuring equitable access to the legal cannabis market.

Industrial issues:

Hemp, defined as C. sativa with less than 0.3% THC, is a sustainable crop with applications in textiles, construction, and nutrition.⁸ Hemp fibers are used for clothing, ropes, and bioplastics, offering durable, eco-friendly alternatives to cotton and petroleum-based materials.⁶ Hemp-based concrete (“hempcrete”) is valued in green construction for its insulation and carbon-sequestering properties.⁴⁸ Hemp seeds, rich in protein, omega-3 fatty acids, and vitamins, are a nutritional powerhouse in foods like hemp milk and protein powders.³³ Hemp seed oil is used in cosmetics for its moisturizing properties.⁴⁹ The 2018 U.S. Farm Bill legalized hemp cultivation, spurring a global market projected to reach $15 billion by 2027.³⁴ Hemp’s environmental benefits are significant. It requires minimal pesticides, improves soil health, and sequesters carbon at a rate comparable to trees.⁴⁴ Its use in bioremediation, absorbing heavy metals from contaminated soil, further enhances its sustainability.⁶ However, challenges include regulatory inconsistencies across countries and the need for scalable processing infrastructure to meet growing demand.

Legal and regulatory issues:

Legal Status and Policy Evolution Cannabis laws vary widely. Recreational use is legal in Canada, Uruguay, and 19 U.S. states, while medical use is permitted in over 50 countries, including Australia, Germany, and Israel.⁴⁵ However, cannabis remains a Schedule I substance under U.S. federal law, classified as having “no accepted medical use,” which restricts research and banking for legal cannabis businesses.³⁶ Europe has seen decriminalization trends, with Portugal and the Netherlands adopting lenient policies that prioritize harm reduction over punishment³⁷. In contrast, many Asian and Middle Eastern nations enforce strict prohibitions, with penalties including imprisonment or death.⁴⁵ Latin America is emerging as a progressive region, with Mexico and Colombia advancing legalization efforts.²⁹ Policy debates center on balancing public health, economic benefits, and social justice.

Legalization has reduced black-market activity and generated tax revenue, but concerns about youth access and impaired driving persist.³¹ Social justice advocates push for expungement of cannabis convictions and equitable participation in the legal market.² Global trends suggest a shift toward reform, though harmonizing international policies remains elusive. Ongoing Research and Challenges Research on Cannabis sativa is expanding, with clinical trials exploring its potential for Alzheimer’s, Parkinson’s, and addiction treatment.^41,42 Preclinical studies suggest cannabinoids may have anti-cancer properties, inhibiting tumor growth in animal models, though human trials are limited.⁴⁰ Cannabis is also studied for mental health, with mixed results: CBD shows promise for anxiety, while THC may exacerbate psychosis in vulnerable populations.³⁵ Challenges include regulatory barriers, particularly in the U.S., where Schedule I status limits access to research-grade cannabis.³⁶ Inconsistent product quality, due to varying cultivation and processing methods, complicates clinical studies.⁴¹ The variability of cannabis products–edibles, vapes, oils, or capsules–creates pharmacokinetic challenges, as bioavailability differs across delivery methods.⁴⁴

Long-term data on recreational use, especially in adolescents, are needed to assess impacts on brain development and mental health.⁴³ International collaboration, standardized testing, and relaxed research restrictions could accelerate progress.⁴² Innovations like nanoparticle delivery systems for cannabinoids may improve therapeutic precision in the future.²²

CONCLUSION:

Cannabis sativa is a plant of unparalleled versatility, with applications spanning medicine, industry, recreation, and culture. Its chemical complexity, historical significance, and evolving legal status underscore its global impact. Medical advancements, from epilepsy treatment to pain management, highlight its therapeutic potential, while hemp’s sustainability drives industrial innovation. However, challenges in regulation, research, and public health require careful navigation. As evidence accumulates and policies evolve, C. sativa will remain a cornerstone of scientific and societal discourse.

REFERENCES:

1. Clarke RC, Merlin MD. Cannabis: Evolution and Ethnobotany. Berkeley: University of California Press; 2013.

2. American Civil Liberties Union. A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform. New York: ACLU; 2020.

3. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007; 4(8): 1614–48.

4. Small E. Evolution and classification of Cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev. 2015; 81(3): 189–294.

5. Kanittha Nakkliang, Onuma Zongram, Chitlada Areesantichai, Kanchana Rungsihirunrat. Assessment of Genetic relationship among Cannabis sativa L. in Thailand based on ISSR and their Phytoconstituents properties. Research Journal of Pharmacy and Technology, 2023; 16(5): 2197-4.

6. Thiruchelvi. R, K. Kavitha, K. Shankari. New Biotechnological Routes for Greener Bio-plastics from Seaweeds. Research J. Pharm. and Tech. 2020; 13(5): 2488-2492.

7. Schultes RE, Hofmann A. The Botany and Chemistry of Hallucinogens. Springfield: Charles C. Thomas; 1980.

8. Namrta Choudhary, M.B. Siddiqui, Shazia, K.M. Abdul Raoof. Phytochemical aspect of Cannabis sativa (L.). Research J. Science and Tech. 2013; 5(2): 284-288.

9. Hillig KW, Mahlberg PG. A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochem Syst Ecol. 2004; 32(10): 875–91.

10. Izzo AA, Borrelli F, Capasso R, et al. non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30(10): 515–27.

11. Chandra S, Lata H, Khan IA, et al. Cannabis cultivation: Methodological issues for obtaining medical-grade product. Epilepsy Behav. 2017; 70(Pt B): 302–12.

12. Ranieri R, Marasco D, Bifulco M, et al. Cannabis and cannabinoids: From traditional medicine to modern therapeutic applications. Curr Med Chem. 2020; 27(22): 3637–55.

13. ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005; 78(5): 539–48.

14. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-THC, CBD and Δ9-THCV. Br J Pharmacol. 2008; 153(2): 199–215.

15. Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015; 12(4): 825–36.

16. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013; 64: 21–47.

17. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011; 163(7): 1344–64.

18. Stott CG, Guy GW. Cannabinoids for the pharmaceutical industry. Euphytica. 2004; 140(1–2): 83–93.

19. Komal Sharma, Rinu Rana, M S Ashawat. Preliminary Phytochemical Screening of Leaves, Stems and Roots of wild Cannabis sativa. Research Journal of Pharmacognosy and Phytochemistry. 2022; 14(1): 19-2.

20. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017; 376(21): 2011–20.

21. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015; 313(24): 2456–73.

22. Cherniakov I, Shlosberg D, Domb AJ, et al. New developments in the delivery of cannabinoids. Drug Deliv Transl Res. 2017; 7(6): 735–47.

23. Swagata Dilip Tavhare, Rabinarayan Acharya, Bhagyashri Vaghora, Vinay Shukla. Comparative evaluation of physicochemical, qualitative and chromatographic profile of unprocessed and processed Cannabis sativa L (Bhanga) leaves. Research Journal of Pharmacy and Technology. 2023; 16(11): 5341-6.

24. Li HL. An archaeological and historical account of cannabis in China. Econ Bot. 1974; 28(4): 437–48.

25. Zuardi AW. History of cannabis as a medicine: A review. Braz J Psychiatry. 2006; 28(2): 153–7.

26. Aarti, Yumnam Devashree. The Phytotoxic Effect of Aqueous extract of Cannabis Sativa on the Germination and Growth of Cicerarietinum. Research J. Pharm. and Tech., 2018; 11(11): 5096-5100.

27. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008; 4(1): 245–59.

28. Lee MA. Smoke Signals: A Social History of Marijuana. New York: Scribner; 2012.

29. Hall W, Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction. 2016; 111(10): 1764–73.

30. Bridgeman MB, Abazia DT. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. Pharm Ther. 2017; 42(3): 180–8.

31. Sarris J, Sinclair J, Karamacoska D, et al. Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review. BMC Psychiatry. 2020; 20(1): 24.

32. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006; 105(1–2): 1–25.

33. Callaway JC. Hempseed as a nutritional resource: An overview. Euphytica. 2004; 140(1): 65–72.

34. Fortune Business Insights. Hemp Market Size, Share & COVID-19 Impact Analysis, 2020–2027. 2020.

35. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol. 2009; 24(7): 515–23.

36. National Institute on Drug Abuse. Marijuana Research Report. Bethesda: NIDA; 2020.

37. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2021: Trends and Developments. Luxembourg: Publications Office of the European Union; 2021.

38. Lynch ME, Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015; 10(2): 293–301.

39. Bachhuber MA, Saloner B, Cunningham CO, et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014; 174(10): 1668–73.

40. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016; 17(6): 739–44.

41. Hangane Ronald, Ketan Patil, Astha Pandey. Detection of Cannabis sativa by various Analytical Techniques. Research Journal of Pharmacy and Technology 2023; 16(6): 2917-0.

42. Abrams DI. The therapeutic effects of cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018; 49: 7–11.

43. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014; 370(23): 2219–27.

44. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018; 49: 12–9.

Received on 22.05.2025 Revised on 17.06.2025

Accepted on 07.07.2025 Published on 24.07.2025

Available online from July 28, 2025

Res. J. Pharmacognosy and Phytochem. 2025; 17(3):247-250.

DOI: 10.52711/0975-4385.2025.00040

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.